Biohaven

BHVN

Market cap $1.57B

11.82 USD

-0.28

2.31%

At close Updated Jan 30, 4:00 PM EST

Pre-market

After hours

11.83

+0.01

0.08%

1 day

-2.31%

5 days

-11.13%

1 month

1.55%

3 months

-32.03%

6 months

-24.23%

Year to date

9.04%

1 year

-69.69%

5 years

65.55%

10 years

65.55%

About: Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Employees: 256

Healthcare Biotechnology